These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776 [Abstract] [Full Text] [Related]
3. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, Hartmann JT. Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060 [Abstract] [Full Text] [Related]
4. Flat dosing of carboplatin is justified in adult patients with normal renal function. Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665 [Abstract] [Full Text] [Related]
7. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y. Cancer Sci; 2010 Dec 01; 101(12):2601-5. PubMed ID: 20860621 [Abstract] [Full Text] [Related]
9. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB. Eur J Cancer; 2014 Mar 01; 50(5):944-52. PubMed ID: 24445148 [Abstract] [Full Text] [Related]
11. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):206-12. PubMed ID: 15156345 [Abstract] [Full Text] [Related]
15. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Ando M, Minami H, Ando Y, Saka H, Sakai S, Yamamoto M, Sasaki Y, Shimokata K, Hasegawa Y. Clin Cancer Res; 2000 Dec 01; 6(12):4733-8. PubMed ID: 11156227 [Abstract] [Full Text] [Related]
16. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Herrington JD, Tran HT, Riggs MW. Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):241-7. PubMed ID: 16133538 [Abstract] [Full Text] [Related]
17. Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature. Kamei K, Sako M, Ishikawa T, Sato M, Ogura M, Uno T, Kiyotani C, Mori T, Tanaka H, Ito S, Nakamura H. Ther Apher Dial; 2015 Oct 01; 19(5):491-6. PubMed ID: 25916242 [Abstract] [Full Text] [Related]
19. Dose-banding of carboplatin: rationale and proposed banding scheme. Kaestner S, Sewell G. J Oncol Pharm Pract; 2007 Jun 01; 13(2):109-17. PubMed ID: 17873111 [Abstract] [Full Text] [Related]
20. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC. Gynecol Oncol; 2006 Dec 01; 103(3):1063-9. PubMed ID: 16875719 [Abstract] [Full Text] [Related] Page: [Next] [New Search]